{'52WeekChange': -0.31580442,
 'SandP52WeekChange': None,
 'address1': '13631 Progress Boulevard',
 'address2': 'Suite 400',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 12.36,
 'askSize': 900,
 'averageDailyVolume10Day': 318700,
 'averageVolume': 511661,
 'averageVolume10days': 318700,
 'beta': 0.409523,
 'beta3Year': None,
 'bid': 11.75,
 'bidSize': 2200,
 'bookValue': 3.125,
 'category': None,
 'circulatingSupply': None,
 'city': 'Alachua',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 12.15,
 'dayLow': 11.64,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -14.267,
 'enterpriseToRevenue': 3.599,
 'enterpriseValue': 387535424,
 'exDividendDate': 1264550400,
 'exchange': 'NCM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '386 462 6801',
 'fiftyDayAverage': 10.586857,
 'fiftyTwoWeekHigh': 18.84,
 'fiftyTwoWeekLow': 7.16,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 25951425,
 'forwardEps': -0.41,
 'forwardPE': -28.682928,
 'fromCurrency': None,
 'fullTimeEmployees': 371,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.03601,
 'heldPercentInstitutions': 0.88807,
 'industry': 'Medical Devices',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 773884800,
 'lastSplitFactor': '105:100',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/axogeninc.com',
 'longBusinessSummary': 'AxoGen, Inc., together with its subsidiaries, '
                        'provides surgical solutions for physical damage or '
                        "transection to peripheral nerves. The company's "
                        'products include Avance Nerve Graft, a biologically '
                        'active off-the-shelf processed human nerve allograft '
                        'for bridging severed nerves without the comorbidities '
                        'associated with a second surgical site; AxoGuard '
                        'Nerve Connector, a porcine submucosa extracellular '
                        'matrix (ECM) coaptation aid for tensionless repair of '
                        'severed peripheral nerves; and AxoGuard Nerve '
                        'Protector, a porcine submucosa ECM product that is '
                        'used to wrap and protect damaged peripheral nerves, '
                        'as well as reinforces the nerve reconstruction while '
                        'preventing soft tissue attachments. Its products also '
                        'comprise Axoguard Nerve Cap, a porcine submucosa ECM '
                        'product that is used to protect a peripheral nerve '
                        'end, as well as separates the nerve from the '
                        'surrounding environment to reduce the development of '
                        'symptomatic or painful neuroma; and Avive Soft Tissue '
                        'Membrane, a minimally processed human umbilical cord '
                        'membrane that can be used as a resorbable soft tissue '
                        'covering to separate tissues in the surgical bed. In '
                        'addition, the company offers AxoTouch two point '
                        'discriminator, a tool that is used for measuring the '
                        'innervation density of surface area of the skin. It '
                        'provides its products to hospitals, surgery centers, '
                        'and military hospitals plastic reconstructive '
                        'surgeons, orthopedic and plastic hand surgeons, and '
                        'various oral and maxillofacial surgeons in the United '
                        'States, Canada, the United Kingdom and other European '
                        'countries, South Korea, and internationally. AxoGen, '
                        'Inc. is headquartered in Alachua, Florida.',
 'longName': 'AxoGen, Inc.',
 'market': 'us_market',
 'marketCap': 467599968,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_20946777',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -27823000,
 'nextFiscalYearEnd': 1640908800,
 'open': 12.04,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '386 462 6800',
 'previousClose': 12.035,
 'priceHint': 2,
 'priceToBook': 3.7632,
 'priceToSalesTrailing12Months': 4.3421736,
 'profitMargins': -0.25837,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 12.15,
 'regularMarketDayLow': 11.64,
 'regularMarketOpen': 12.04,
 'regularMarketPreviousClose': 12.035,
 'regularMarketPrice': 12.04,
 'regularMarketVolume': 136802,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 39761900,
 'sharesPercentSharesOut': 0.032,
 'sharesShort': 1270654,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1177428,
 'shortName': 'AxoGen, Inc.',
 'shortPercentOfFloat': 0.039100002,
 'shortRatio': 3.34,
 'startDate': None,
 'state': 'FL',
 'strikePrice': None,
 'symbol': 'AXGN',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.706,
 'twoHundredDayAverage': 10.795899,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '7bcdc4f6-2582-3323-ab9e-9d3722f90de9',
 'volume': 136802,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.axogeninc.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '32615'}